Table 1. Efficiency of CRISPR/Cas9-mediated gene targeting depends on sgRNAs sequence features.
| sgRNA | Blastocysts/injected oocytes (blastocyst rate) | No. of tested blastocysts | Monoallelic mutants (% of tested) | Biallelic mutants (% of tested) |
|---|---|---|---|---|
| Water | 29/103 (28.16%) | \ | \ | \ |
| F1 | 106/383 (27.68%) | 41 | 21 (51.22) | 4 (9.76) |
| F2 | 98/377 (25.99%) | 30 | 6 (20.00) | 9 (30.00) |
| R1 | 95/357 (26.61%) | 55 | 7 (12.73) | 38 (69.09) |
| R2 | 87/342 (25.44%) | 38 | 22 (57.89) | 4 (10.53) |
Comparison of in vitro development of CRISPR/Cas9-injected oocytes and mutagenesis efficiency between different sgRNAs.